Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Saxenda® provides consistent weight loss and improvements in blood glucose control across BMI categories after three years of treatment

Novo Nordisk A/S
Posted on: 14 Sep 16

Munich, Germany, 14 September 2016 - Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show that people treated with Saxenda ® (liraglutide 3 mg) experienced consistent weight loss and improved blood glucose control across baseline body mass index (BMI) categories over three years as compared to placebo treatment. These data were presented today at the 52 nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.

Further information

Katrine Sperling+45 4442 6718
Åsa Josefsson+45 3079 7708
Investors :    
Peter Hugreffe Ankersen+45 3075 9085
Melanie Raouzeos+45 3075 3479
Hanna Ögren+45 3079 8519
Kasper Veje (US)+1 609 235 8567
Read the full release including references

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire

Last updated on: 15/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.